Kymera Therapeutics, Inc. (KYMR)

Kymera Therapeutics' stock has been impacted by positive clinical results from the Phase 1b trial of KT-621, and the company closed an upsized $602 million public offering. Kymera outlined its 2026 objectives and strategy to advance its oral immunology programs, and dosing was initiated in the BREADTH Phase 2b clinical trial evaluating KT-621 in patients with eosinophilic asthma. Kymera Therapeutics received a "Buy" rating from BTIG Research, and several analysts have maintained "Buy" or "Overweight" ratings and raised price targets, though Wall Street Zen downgraded the stock to a "Sell" rating in March 2026. Insider selling activity was noted in December 2025, and further sales by the COO and CEO were reported in March and February 2026, respectively. Kymera reported Q4 and full-year 2025 results, including $1.6 billion in cash, positive KT-621 Phase 1b atopic dermatitis data, and the initiation of KT-579 Phase 1 dosing; the stock experienced a moderate positive market reaction.

As a clinical-stage biopharmaceutical company without commercial products, Kymera Therapeutics does not experience demand seasonality. Its revenue is primarily generated through collaborative research and development agreements, making its financial performance tied to clinical trial progress and the achievement of milestone payments.

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule therapies using its proprietary Pegasus™ platform for targeted protein degradation (TPD). The company's pipeline primarily focuses on immunology-inflammation and oncology, with key product candidates including KT-621, KT-474/SAR444656, KT-579, a CDK2 Molecular Glue Degrader, the IRAKIMiD program, the STAT3 program, and the MDM2 program. KT-621 is in Phase 2b clinical trials for atopic dermatitis and asthma and has received FDA Fast Track designation for atopic dermatitis. KT-474/SAR444656 is in Phase 2b trials for immunology-inflammation diseases in collaboration with Sanofi S.A. KT-579 is expected to enter Phase 1 trials in early 2026 for autoimmune diseases, with dosing initiated in February 2026. The CDK2 Molecular Glue Degrader is partnered with Gilead Sciences for oncology. The IRAKIMiD program is aimed at treating MYD88-mutated diffuse large B cell lymphoma. The STAT3 program is for hematologic malignancies, solid tumors, autoimmune diseases, and fibrosis. The MDM2 program is for hematological malignancies and solid tumors.

Kymera Therapeutics, Inc. is headquartered in Watertown, Massachusetts, and was initially incubated in Cambridge, Massachusetts. The company's collaborations with partners such as Sanofi S.A. and Gilead Sciences suggest a broader reach for its drug development and potential commercialization efforts.

Kymera Therapeutics has maintained a positive brand reputation over the past year, receiving a consensus "Buy" rating from analysts and positive ratings from investing groups. Positive clinical trial results for KT-621 boosted its reputation. Collaborations with major pharmaceutical companies like Sanofi and Gilead Sciences validate its platform and contribute to a favorable outlook. The company's robust cash position and mission also contribute to a positive perception.

Kymera Therapeutics, Inc.'s ownership is heavily weighted towards institutional funds, which hold over 100% of the publicly available float, with insiders holding approximately 16.01% of the stock. Major institutional owners include Baker Bros. Advisors Lp, Fmr Llc, Avoro Capital Advisors LLC, Vanguard Group Inc (The Vanguard Group, Inc.), Wellington Management Group Llp, Price T Rowe Associates Inc /md/ (T. Rowe Price Group, Inc.), Bvf Inc/il (BVF Partners L.P.), BlackRock, Inc., Atlas Venture Life Science Advisors, LLC (Atlas Venture Advisors, Inc.), Siren, L.L.C., and State Street Corp.